Nagavendra Kommineni

Dr. Nagavendra Kommineni

Center for Biomedical Research (CBR) Population Council, Rockefeller University
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2017 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
UBUpendra Bulbake
Upendra Bulbake
SDSindhu Doppalapudi
Sindhu Doppalapudi
Nagavendra KommineniNagavendra Kommineni
Nagavendra Kommineni
WKwahid khan
wahid khan
Liposomes are the first nano drug delivery systems that have been successfully translated into real-time clinical applications. These closed bilayer phospholipid vesicles have witnessed many technical advances in recent years since their first development in 1965. Delivery of therapeutics by liposomes alters their biodistribution profile, which further enhances the therapeutic index of various drugs. Extensive research is being carried out using these nano drug delivery systems in diverse areas including the delivery of anti-cancer, anti-fungal, anti-inflammatory drugs and therapeutic genes. The significant contribution of liposomes as drug delivery systems in the healthcare sector is known by many clinical products, e.g., Doxil®, Ambisome®, DepoDur™, etc. This review provides a detailed update on liposomal technologies e.g., DepoFoam™ Technology, Stealth technology, etc., the formulation aspects of clinically used products and ongoing clinical trials on liposomes.

21 April 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Nimeet DesaiNimeet Desai
Nimeet Desai
DRDhwani Rana
Dhwani Rana
Sagar SalaveSagar Salave
Sagar Salave
RGRaghav Gupta
Raghav Gupta
PPPranav Patel
Pranav Patel
Nagavendra KommineniNagavendra Kommineni
Nagavendra Kommineni
Chitosan, a biocompatible and biodegradable polysaccharide derived from chitin, has surfaced as a material of promise for drug delivery and biomedical applications. Different chitin and chitosan extraction techniques can produce materials with unique properties, which can be further modified to enhance their bioactivities. Chitosan-based drug delivery systems have been developed for various routes of administration, including oral, ophthalmic, transdermal, nasal, and vaginal, allowing for targeted and sustained release of drugs. Additionally, chitosan has been used in numerous biomedical applications, such as bone regeneration, cartilage tissue regeneration, cardiac tissue regeneration, corneal regeneration, periodontal tissue regeneration, and wound healing. Moreover, chitosan has also been utilized in gene delivery, bioimaging, vaccination, and cosmeceutical applications. Modified chitosan derivatives have been developed to improve their biocompatibility and enhance their properties, resulting in innovative materials with promising potentials in various biomedical applications. This article summarizes the recent findings on chitosan and its application in drug delivery and biomedical science.

Verified
Journal Article
Open access
Vrinda GoteVrinda Gote
Vrinda Gote
Pradeep Kumar BollaPradeep Kumar Bolla
Pradeep Kumar Bolla
Nagavendra KommineniNagavendra Kommineni
Nagavendra Kommineni
ABArun Butreddy
Arun Butreddy
PAVAN KUMAR NUKALAPAVAN KUMAR NUKALA
PAVAN KUMAR NUKALA
WKwahid khan
wahid khan
MRNA vaccines have been demonstrated as a powerful alternative to traditional conventional vaccines because of their high potency, safety and efficacy, capacity for rapid clinical development, and potential for rapid, low-cost manufacturing. These vaccines have progressed from being a mere curiosity to emerging as COVID-19 pandemic vaccine front-runners. The advancements in the field of nanotechnology for developing delivery vehicles for mRNA vaccines are highly significant. In this review we have summarized each and every aspect of the mRNA vaccine. The article describes the mRNA structure, its pharmacological function of immunity induction, lipid nanoparticles (LNPs), and the upstream, downstream, and formulation process of mRNA vaccine manufacturing. Additionally, mRNA vaccines in clinical trials are also described. A deep dive into the future perspectives of mRNA vaccines, such as its freeze-drying, delivery systems, and LNPs targeting antigen-presenting cells and dendritic cells, are also summarized.

18 June 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
PPPalpandi Pandi
Palpandi Pandi
RBRaviteja Bulusu
Raviteja Bulusu
Nagavendra KommineniNagavendra Kommineni
Nagavendra Kommineni
WKwahid khan
wahid khan
Mandip Singh SachdevaMandip Singh Sachdeva
Mandip Singh Sachdeva

Verified
Journal Article
Open access
PDF file
ABArun Butreddy
Arun Butreddy
RGRajendra Prasad Gaddam
Rajendra Prasad Gaddam
Nagavendra KommineniNagavendra Kommineni
Nagavendra Kommineni
NDNarendar Dudhipala
Narendar Dudhipala
CVCHANDRA SHEKHAR VOSHAVAR
CHANDRA SHEKHAR VOSHAVAR
Over the past few decades, long acting injectable (LAI) depots of polylactide-co-glycolide (PLGA) or polylactic acid (PLA) based microspheres have been developed for controlled drug delivery to reduce dosing frequency and to improve the therapeutic effects. Biopharmaceuticals such as proteins and peptides are encapsulated in the microspheres to increase their bioavailability and provide a long release period (days or months) with constant drug plasma concentration. The biodegradable and biocompatible properties of PLGA/PLA polymers, including but not limited to molecular weight, end group, lactide to glycolide ratio, and minor manufacturing changes, could greatly affect the quality attributes of microsphere formulations such as release profile, size, encapsulation efficiency, and bioactivity of biopharmaceuticals. Besides, the encapsulated proteins/peptides are susceptible to harsh processing conditions associated with microsphere fabrication methods, including exposure to organic solvent, shear stress, and temperature fluctuations. The protein/peptide containing LAI microspheres in clinical use is typically prepared by double emulsion, coacervation, and spray drying techniques. The purpose of this review is to provide an overview of the formulation attributes and conventional manufacturing techniques of LAI microspheres that are currently in clinical use for protein/peptides. Furthermore, the physicochemical characteristics of the microsphere formulations are deliberated.

3 June 2021 in Nanomaterials
Verified
Journal Article
Open access
PDF file
ABArun Butreddy
Arun Butreddy
Nagavendra KommineniNagavendra Kommineni
Nagavendra Kommineni
NDNarendar Dudhipala
Narendar Dudhipala
Exosomes as nanosized vesicles are emerging as drug delivery systems for therapeutics owing to their natural origin, their ability to mediate intercellular communication, and their potential to encapsulate various biological molecules such as proteins and nucleic acids within the lipid bilayer membrane or in the lumen. Exosomes contain endogenous components (proteins, lipids, RNA) that could be used to deliver cargoes to target cells, offering an opportunity to diagnose and treat various diseases. Owing to their ability to travel safely in extracellular fluid and to transport cargoes to target cells with high efficacy, exosomes offer enhanced delivery of cargoes in vivo. However, several challenges related to the stabilization of the exosomes, the production of sufficient amounts of exosomes with safety and efficacy, the efficient loading of drugs into exosomes, the clearance of exosomes from circulation, and the transition from the bench scale to clinical production may limit their development and clinical use. For the clinical use of exosomes, it is important to understand the molecular mechanisms behind the transport and function of exosome vesicles. This review exploits techniques related to the isolation and characterization of exosomes and their drug delivery potential to enhance the therapeutic outcome and stabilization methods. Further, routes of administration, clinical trials, and regulatory aspects of exosomes will be discussed in this review.